PT Sarana Meditama Metropolitan Tbk

IDX:SAME Stock Report

Market Cap: Rp4.9t

Sarana Meditama Metropolitan Past Earnings Performance

Past criteria checks 0/6

Sarana Meditama Metropolitan has been growing earnings at an average annual rate of 41.2%, while the Healthcare industry saw earnings growing at 3.7% annually. Revenues have been growing at an average rate of 22.5% per year.

Key information

41.2%

Earnings growth rate

53.5%

EPS growth rate

Healthcare Industry Growth14.1%
Revenue growth rate22.5%
Return on equity0.2%
Net Margin-0.07%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sarana Meditama Metropolitan makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IDX:SAME Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,689,899-1,146491,9390
30 Jun 241,660,5918,714496,2540
31 Mar 241,606,82411,935469,6690
31 Dec 231,535,64012,252474,6900
30 Sep 231,502,78720,605413,7150
30 Jun 231,478,33727,631400,6920
31 Mar 231,408,664-53430,0460
31 Dec 221,393,5424,347413,7150
30 Sep 221,302,502-11,232408,3060
30 Jun 221,261,61031,503376,0480
31 Mar 221,292,050122,081353,3140
31 Dec 211,271,584144,169325,9660
30 Sep 211,313,296419,138313,8670
30 Jun 211,249,044-52,297357,4580
31 Mar 211,009,192-141,633317,7020
31 Dec 20816,816-187,643290,2870
30 Sep 20623,730-479,066254,8150
30 Jun 20222,708-166,670142,2900
31 Mar 20391,003-136,323169,6310
31 Dec 19529,320-114,385198,2030
30 Sep 19654,680-84,522212,7850
30 Jun 191,026,68015,990264,7050
31 Mar 191,004,60341,958255,5130
31 Dec 18952,08258,883233,4330
30 Sep 18898,94651,322220,5320
30 Jun 18853,59673,173211,4960
31 Mar 18816,99570,484199,7330
31 Dec 17775,56772,015188,6140
30 Sep 17730,24778,624175,5300
30 Jun 17693,97162,171173,1800
31 Mar 17672,57512,557176,5350
31 Dec 16635,02114,795169,9820
30 Sep 16617,31027,814167,9370
30 Jun 16579,95024,642152,6390
31 Mar 16542,63867,647137,8370
31 Dec 15515,09556,605129,6120
30 Sep 15487,02951,892124,6420
30 Jun 15465,64862,791120,8520
31 Mar 15441,23359,846112,5630
31 Dec 14414,41557,708108,0770
30 Sep 14389,34757,96698,9730
30 Jun 14372,68654,30296,4600
31 Mar 14352,41551,01193,9470
31 Dec 13336,51146,64988,8590

Quality Earnings: SAME is currently unprofitable.

Growing Profit Margin: SAME is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SAME is unprofitable, but has reduced losses over the past 5 years at a rate of 41.2% per year.

Accelerating Growth: Unable to compare SAME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SAME is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (2.7%).

Return on Equity

High ROE: SAME has a negative Return on Equity (0.19%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 13:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Sarana Meditama Metropolitan Tbk is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel SentanaDeutsche Bank
Herman TjahjadiRHB Investment Bank